Replication	O
Inhibition	O
of	O
Hepatitis	B-OG
B	I-OG
Virus	I-OG
and	O
Hepatitis	B-OG
C	I-OG
Virus	I-OG
in	O
Co	O
-	O
Infected	O
Patients	O
in	O
Chinese	O
Population	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
JQN	O
YP	O
.	O

Performed	O
the	O
experiments	O
:	O
GY	O
XMC	O
XMW	O
XZG	O
XWF	O
YDG	O
YP	O
FK	O
XXH	O
JLJ	O
YQ	O
.	O

Analyzed	O
the	O
data	O
:	O
GY	O
RHW	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
JQN	O
XMC	O
.	O

Wrote	O
the	O
paper	O
:	O
GY	O
XMC	O
ZKT	O
BS	O
JZ	O
.	O

Background	O

Hepatitis	O
B	O
virus	B-OG
(	O
HBV	B-OG
)	O
and	O
hepatitis	B-OG
C	I-OG
virus	I-OG
(	O
HCV	B-OG
)	O
co	B-DS
-	I-DS
infections	I-DS
contributes	O
to	O
a	O
substantial	O
proportion	O
of	O
liver	B-DS
disease	I-DS
worldwide	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
clinical	O
and	O
virological	O
features	O
of	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
.	O

Methods	O

Demographic	O
data	O
were	O
collected	O
for	O
3238	O
high	O
-	O
risk	O
people	O
from	O
an	O
HCV	B-OG
-	O
endemic	O
region	O
in	O
China	O
.	O

Laboratory	O
tests	O
included	O
HCV	B-OG
antibody	B-GP
and	O
HBV	B-OG
serological	O
markers	O
,	O
liver	O
function	O
tests	O
,	O
and	O
routine	O
blood	O
analysis	O
.	O

Anti	O
-	O
HCV	B-OG
positive	O
samples	O
were	O
analyzed	O
for	O
HCV	B-OG
RNA	O
levels	O
and	O
subgenotypes	O
.	O

HBsAg	B-GP
-	O
positive	O
samples	O
were	O
tested	O
for	O
HBV	B-OG
DNA	O
.	O

Results	O

A	O
total	O
of	O
1468	O
patients	O
had	O
chronic	O
HCV	B-OG
and	O
/	O
or	O
HBV	B-DS
infections	I-DS
.	O

Among	O
them	O
,	O
1200	O
individuals	O
were	O
classified	O
as	O
HCV	B-OG
mono	O
-	O
infected	O
,	O
161	O
were	O
classified	O
as	O
HBV	B-OG
mono	O
-	O
infected	O
,	O
and	O
107	O
were	O
classified	O
as	O
co	O
-	O
infected	O
.	O

The	O
HBV	B-OG
-	O
HCV	B-OG
co	O
-	O
infected	O
patients	O
not	O
only	O
had	O
a	O
lower	O
HBV	B-OG
DNA	O
positive	O
rate	O
compared	O
to	O
HBV	B-OG
mono	O
-	O
infected	O
patients	O
(	O
84	O
.	O
1	O
%	O
versus	O
94	O
.	O
4	O
%,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
001	O
).	O

The	O
median	O
HCV	B-OG
RNA	O
levels	O
in	O
HBV	B-OG
-	O
HCV	B-OG
co	O
-	O
infected	O
patients	O
were	O
significantly	O
lower	O
than	O
those	O
in	O
the	O
HCV	B-OG
mono	O
-	O
infected	O
patients	O
(	O
1	O
.	O
18	O
[	O
Interquartile	O
range	O
(	O
IQR	O
)	O
0	O
–	O
5	O
.	O
57	O
]	O
versus	O
5	O
.	O
87	O
[	O
IQR	O
,	O
3	O
.	O
54	O
–	O
6	O
.	O
71	O
]	O
Log10	O
IU	O
/	O
mL	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
001	O
).	O

Furthermore	O
,	O
co	O
-	O
infected	O
patients	O
were	O
less	O
likely	O
to	O
have	O
detectable	O
HCV	B-OG
RNA	O
levels	O
than	O
HCV	B-OG
mono	O
-	O
infected	O
patients	O
(	O
23	O
.	O
4	O
%	O
versus	O
56	O
.	O
5	O
%,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
001	O
).	O

Those	O
HBV	B-OG
-	O
HCV	B-OG
co	O
-	O
infected	O
patients	O
had	O
significantly	O
lower	O
median	O
HBV	B-OG
DNA	O
levels	O
than	O
those	O
mono	O
-	O
infected	O
with	O
HBV	B-OG
(	O
1	O
.	O
97	O
[	O
IQR	O
,	O
1	O
.	O
3	O
–	O
3	O
.	O
43	O
]	O
versus	O
3	O
.	O
06	O
[	O
IQR	O
,	O
2	O
–	O
4	O
.	O
28	O
]	O
Log10	O
IU	O
/	O
mL	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
001	O
).	O

The	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
group	O
had	O
higher	O
ALT	B-GP
,	O
AST	B-GP
,	O
ALP	B-GP
,	O
GGT	B-GP
,	O
APRI	O
and	O
FIB	O
-	O
4	O
levels	O
,	O
but	O
lower	O
ALB	B-GP
and	O
total	O
platelet	O
compared	O
to	O
the	O
HBV	B-OG
mono	O
-	O
infection	B-DS
group	O
,	O
and	O
similar	O
to	O
that	O
of	O
the	O
HCV	B-OG
mono	O
-	O
infected	O
group	O
.	O

Conclusion	O

These	O
results	O
suggest	O
that	O
co	B-DS
-	I-DS
infection	I-DS
with	O
HCV	B-OG
and	O
HBV	B-OG
inhibits	O
the	O
replication	O
of	O
both	O
viruses	B-OG
.	O

The	O
serologic	O
results	O
of	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
in	O
patients	O
suggests	O
more	O
liver	O
injury	O
compared	O
to	O
HBV	B-OG
mono	O
-	O
infected	O
patients	O
,	O
but	O
is	O
similar	O
to	O
HCV	B-OG
mono	O
-	O
infection	B-DS
.	O

Introduction	O

Hepatitis	O
B	O
virus	B-OG
(	O
HBV	B-OG
)	O
and	O
hepatitis	B-OG
C	I-OG
virus	I-OG
(	O
HCV	B-OG
)	O
infections	B-DS
are	O
the	O
most	O
common	O
causes	O
of	O
liver	B-DS
disease	I-DS
worldwide	O
.	O

An	O
estimated	O
350	O
million	O
individuals	O
have	O
chronic	O
HBV	B-DS
infection	I-DS
,	O
and	O
170	O
million	O
individuals	O
have	O
chronic	O
HCV	B-DS
infection	I-DS
[	O
1	O
–	O
3	O
].	O

HBV	B-OG
and	O
HCV	B-OG
have	O
similar	O
modes	O
of	O
transmission	O
[	O
4	O
],	O
and	O
co	B-DS
-	I-DS
infections	I-DS
occurs	O
frequently	O
in	O
endemic	O
areas	O
[	O
3	O
,	O
5	O
].	O

Importantly	O
,	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
is	O
associated	O
with	O
more	O
severe	O
liver	B-DS
disease	I-DS
and	O
with	O
a	O
higher	O
prevalence	O
of	O
liver	B-DS
cancer	I-DS
[	O
4	O
].	O

HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
involves	O
complex	O
viral	O
interaction	O
.	O

Interference	O
between	O
HBV	B-OG
and	O
HCV	B-OG
in	O
co	O
-	O
infected	O
patients	O
resulting	O
in	O
the	O
suppression	O
of	O
viral	O
replication	O
has	O
been	O
described	O
[	O
1	O
,	O
5	O
–	O
9	O
].	O

While	O
liver	B-DS
disease	I-DS
activity	O
and	O
fibrosis	O
progression	O
are	O
generally	O
more	O
severe	O
in	O
cases	O
of	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
,	O
an	O
inverse	O
relationship	O
between	O
the	O
replication	O
of	O
each	O
virus	B-OG
within	O
some	O
co	O
-	O
infected	O
patients	O
has	O
been	O
noted	O
,	O
suggesting	O
direct	O
or	O
indirect	O
viral	O
interference	O
[	O
10	O
,	O
11	O
].	O

Challenging	O
this	O
notion	O
,	O
longitudinal	O
studies	O
revealed	O
that	O
the	O
two	O
viruses	B-OG
may	O
replicate	O
independently	O
within	O
some	O
patients	O
,	O
causing	O
fluctuations	O
in	O
the	O
serum	O
level	O
of	O
one	O
virus	B-OG
that	O
appear	O
unrelated	O
to	O
the	O
viremia	B-DS
of	O
the	O
other	O
[	O
7	O
].	O

Suppression	O
of	O
HBV	B-OG
replication	O
has	O
been	O
observed	O
in	O
patients	O
with	O
chronic	O
HBV	B-DS
infection	I-DS
after	O
acute	B-DS
infection	I-DS
with	O
HCV	B-OG
;	O
similarly	O
,	O
inhibition	O
of	O
HCV	B-OG
replication	O
has	O
been	O
observed	O
in	O
patients	O
with	O
chronic	O
HCV	B-OG
superinfected	O
with	O
HBV	B-OG
[	O
8	O
,	O
12	O
].	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
virological	O
features	O
of	O
HBV	B-OG
-	O
HCV	B-OG
co	O
-	O
infected	O
patients	O
.	O

In	O
patients	O
with	O
chronic	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
,	O
more	O
rapid	O
hepatitis	B-GP
B	I-GP
extracellular	I-GP
antigen	I-GP
(	O
HBeAg	B-GP
)	O
seroconversion	O
and	O
hepatitis	B-GP
B	I-GP
virus	I-GP
surface	I-GP
antigen	I-GP
(	O
HBsAg	B-GP
)	O
clearance	O
have	O
been	O
documented	O
[	O
13	O
,	O
14	O
].	O

Compared	O
to	O
HBV	B-OG
mono	O
-	O
infected	O
patients	O
,	O
HBsAg	B-GP
carriers	O
with	O
concurrent	O
HCV	B-OG
infection	B-DS
have	O
low	O
-	O
level	O
HBV	B-DS
viremia	I-DS
,	O
low	O
titers	O
of	O
HBsAg	B-GP
in	O
serum	O
,	O
and	O
low	O
-	O
levels	O
of	O
intracellular	O
HBsAg	B-GP
[	O
15	O
].	O

Furthermore	O
,	O
HBsAg	B-GP
serum	O
titers	O
are	O
significantly	O
lower	O
during	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
,	O
potentially	O
due	O
to	O
decreased	O
HBV	B-OG
replication	O
[	O
16	O
].	O

HCV	B-OG
core	B-GP
antigen	I-GP
and	O
HCV	B-OG
RNA	O
are	O
positively	O
correlated	O
and	O
appear	O
almost	O
simultaneously	O
in	O
patients	O
’	O
peripheral	O
blood	O
,	O
suggesting	O
HCV	B-OG
core	B-GP
antigen	I-GP
may	O
be	O
an	O
additional	O
useful	O
diagnostic	O
marker	O
[	O
17	O
–	O
19	O
].	O

However	O
,	O
no	O
studies	O
have	O
previously	O
correlated	O
HCV	B-OG
core	B-GP
antigen	I-GP
levels	O
with	O
serum	O
HCV	B-OG
RNA	O
in	O
patients	O
with	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
.	O

Therefore	O
,	O
we	O
studied	O
the	O
effect	O
of	O
HCV	B-OG
replication	O
and	O
HCV	B-OG
core	B-GP
Ag	I-GP
expression	O
in	O
patients	O
with	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
.	O

We	O
investigated	O
the	O
viral	O
interactions	O
in	O
HBV	B-OG
-	O
HCV	B-OG
co	O
-	O
infected	O
patients	O
in	O
an	O
HCV	B-OG
-	O
endemic	O
region	O
.	O

This	O
study	O
included	O
a	O
large	O
cohort	O
of	O
patients	O
with	O
chronic	B-DS
hepatitis	I-DS
due	O
to	O
HCV	B-OG
and	O
/	O
or	O
HBV	B-DS
infections	I-DS
.	O

In	O
this	O
study	O
,	O
we	O
collected	O
clinical	O
and	O
serological	O
/	O
virological	O
data	O
,	O
compared	O
these	O
data	O
among	O
the	O
HBV	B-OG
mono	O
-	O
infected	O
,	O
HCV	B-OG
mono	O
-	O
infected	O
,	O
and	O
HBV	B-OG
-	O
HCV	B-OG
co	O
-	O
infected	O
groups	O
,	O
and	O
correlated	O
the	O
findings	O
with	O
the	O
degree	O
of	O
liver	O
injury	O
.	O

Methods	O

Study	O
Population	O

A	O
total	O
of	O
3238	O
high	O
risk	O
patients	O
had	O
previously	O
been	O
enrolled	O
in	O
a	O
prior	O
HCV	B-OG
study	O
entitled	O
“	O
Epidemiological	O
investigation	O
of	O
Hepatitis	B-DS
C	I-DS
virus	I-DS
infection	I-DS
in	O
FuYu	O
country	O
of	O
Jilin	O
Province	O
”	O
on	O
September	O
2012	O
(	O
unpublished	O
observations	O
).”	O
Patients	O
were	O
eligible	O
for	O
the	O
study	O
if	O
they	O
were	O
18	O
years	O
of	O
age	O
or	O
older	O
.	O

Participants	O
completed	O
questionnaires	O
and	O
underwent	O
comprehensive	O
medical	O
examinations	O
including	O
liver	O
ultrasound	O
,	O
anthropometric	O
measurements	O
,	O
and	O
blood	O
analysis	O
to	O
measure	O
markers	O
for	O
liver	O
function	O
and	O
injury	O
,	O
including	O
alanine	B-GP
transaminase	I-GP
(	O
ALT	B-GP
),	O
aspartate	B-GP
aminotransferase	I-GP
(	O
AST	B-GP
),	O
alkaline	B-GP
phosphatase	I-GP
(	O
ALP	B-GP
),	O
gama	B-GP
-	I-GP
glutamyltransferase	I-GP
(	O
GGT	B-GP
),	O
and	O
albumin	B-GP
(	O
ALB	B-GP
).	O

Additionally	O
,	O
two	O
values	O
were	O
calculated	O
to	O
determine	O
fibrosis	O
in	O
liver	O
:	O
AST	B-GP
to	O
platelet	O
ration	O
index	O
(	O
APRI	O
)	O
and	O
the	O
Fibrosis	O
-	O
4	O
score	O
(	O
FIB	O
-	O
4	O
).	O

Other	O
tests	O
included	O
assays	O
for	O
detecting	O
serum	O
HCV	B-OG
antibody	B-GP
,	O
HBV	B-OG
serological	O
markers	O
,	O
HCV	B-OG
RNA	O
,	O
and	O
HBV	B-OG
DNA	O
.	O

In	O
all	O
test	O
groups	O
,	O
individuals	O
with	O
hepatitis	B-OG
D	I-OG
virus	I-OG
(	O
HDV	B-OG
)	O
or	O
HIV	B-DS
-	I-DS
1	I-DS
infection	I-DS
were	O
excluded	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
individuals	O
and	O
the	O
study	O
protocol	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
First	O
Hospital	O
of	O
Jilin	O
University	O
.	O

Viral	O
Genotype	O
,	O
Viral	O
Load	O
,	O
and	O
Other	O
Biochemical	O
Measurements	O

Serological	O
markers	O
for	O
anti	O
-	O
HCV	B-OG
,	O
HBsAg	B-GP
,	O
and	O
anti	O
-	O
HIV	B-OG
antibodies	B-GP
were	O
measured	O
using	O
a	O
Thermo	O
Scientific	O
Multiskan	O
Go	O
(	O
Kehua	O
,	O
Shanghai	O
,	O
China	O
).	O

HCV	B-OG
genotyping	O
was	O
performed	O
by	O
multicolor	O
fluorescence	O
PCR	O
using	O
an	O
HCV	B-OG
RNA	O
genotype	O
kit	O
(	O
BioAssay	O
Science	O
&	O
Technology	O
Co	O
.	O

Ltd	O
,	O
China	O
).	O

The	O
levels	O
of	O
HBsAg	B-GP
serological	O
markers	O
was	O
measured	O
using	O
the	O
Elecsys	O
2010	O
and	O
Roche	O
COBAS	O
e	O
411	O
Immunoassay	O
System	O
(	O
Roche	O
Diagnostics	O
,	O
Grenzach	O
,	O
Germany	O
).	O

Serum	O
HCV	B-OG
RNA	O
and	O
HBV	B-OG
DNA	O
levels	O
were	O
measured	O
using	O
the	O
COBAS	O
AmpliPrep	O
/	O
COBAS	O
TaqMan	O
assay	O
(	O
Roche	O
Molecular	O
Diagnostics	O
,	O
Grenzach	O
,	O
Germany	O
)	O
with	O
a	O
detection	O
limit	O
of	O
15	O
U	O
/	O
mL	O
.	O

Biochemical	O
assays	O
were	O
performed	O
using	O
a	O
Synchron	O
LX	O
®	O
20	O
Autoanalyzer	O
(	O
Beckman	O
Coulter	O
,	O
Brea	O
,	O
CA	O
).	O

Serum	O
HCV	B-OG
core	B-GP
Ag	I-GP
was	O
measured	O
using	O
an	O
Abbott	O
Architect	O
i2000SR	O
Analyzer	O
(	O
Abbott	O
Laboratories	O
,	O
Abbott	O
Park	O
,	O
IL	O
,	O
USA	O
)	O
with	O
an	O
HCV	B-OG
core	B-GP
Ag	I-GP
assay	O
kit	O
(	O
Abbott	O
Japan	O
Co	O
.,	O
Ltd	O
.,	O
Tokyo	O
,	O
Japan	O
).	O

Statistical	O
Analysis	O

Normally	O
distributed	O
variables	O
are	O
presented	O
as	O
mean	O
±	O
standard	O
deviation	O
(	O
SD	O
),	O
and	O
differences	O
were	O
evaluated	O
by	O
Student	O
’	O
s	O
t	O
test	O
or	O
analysis	O
of	O
variance	O
.	O

Non	O
-	O
normally	O
distributed	O
variables	O
are	O
presented	O
as	O
median	O
(	O
interquartile	O
range	O
,	O
IQR	O
),	O
and	O
differences	O
were	O
tested	O
by	O
Wilcoxon	O
rank	O
-	O
sum	O
test	O
or	O
Kruskal	O
–	O
Wallis	O
test	O
,	O
as	O
appropriate	O
.	O

Categorical	O
variables	O
are	O
expressed	O
as	O
frequencies	O
(%),	O
and	O
differences	O
were	O
assessed	O
using	O
the	O
Pearson	O
Chi	O
-	O
square	O
test	O
.	O

A	O
two	O
-	O
tailed	O
P	O
value	O
≤	O
0	O
.	O
05	O
was	O
considered	O
statistically	O
significant	O
.	O

Statistical	O
analyses	O
were	O
performed	O
using	O
the	O
SPSS	O
version	O
18	O
.	O
0	O
software	O
(	O
IBM	O
/	O
S	O
PSS	O
Inc	O
.,	O
Chicago	O
,	O
IL	O
).	O

Results	O

Characteristics	O
of	O
Patients	O

The	O
study	O
population	O
included	O
1468	O
individuals	O
with	O
chronic	O
HCV	B-OG
and	O
/	O
or	O
HBV	B-OG
(	O
anti	O
-	O
HIV	B-OG
and	O
anti	O
-	O
HDV	B-OG
negative	O
).	O

Among	O
them	O
,	O
1200	O
were	O
mono	O
-	O
infected	O
with	O
HCV	B-OG
(	O
anti	O
-	O
HCV	B-OG
positive	O
),	O
161	O
were	O
mono	O
-	O
infected	O
with	O
HBV	B-OG
(	O
HBsAg	B-GP
positive	O
),	O
and	O
107	O
were	O
co	O
-	O
infected	O
with	O
HBV	B-OG
and	O
HCV	B-OG
(	O
HBsAg	B-GP
and	O
anti	O
-	O
HCV	B-OG
positive	O
).	O

Demographic	O
and	O
clinical	O
characteristics	O
are	O
summarized	O
in	O
Table	O
1	O
.	O

Demographic	O
and	O
clinical	O
characteristics	O
of	O
the	O
Patient	O
cohort	O
.	O

HBV	B-OG

HCV	B-OG

HBV	B-OG
-	O
HCV	B-OG

Characteristic	O

(	O
N	O
=	O
161	O
)	O

(	O
N	O
=	O
1200	O
)	O

(	O
N	O
=	O
107	O
)	O

P	O
Value	O

Age	O
(	O
years	O
),	O
mean	O
(	O
SD	O
)	O

46	O
.	O
5	O
(	O
9	O
.	O
6	O
)	O
▲	O

54	O
.	O
2	O
(	O
8	O
.	O
9	O
)*	O

52	O
.	O
1	O
(	O
7	O
.	O
3	O
)	O
#	O

<	O
0	O
.	O
001	O

Age	O
(	O
years	O
)	O
<	O
50	O

104	O
(	O
64	O
.	O
6	O
)	O

372	O
(	O
31	O
.	O
0	O
)	O

43	O
(	O
40	O
.	O
2	O
)	O

<	O
0	O
.	O
001	O

50	O
–	O
59	O

45	O
(	O
28	O
.	O
0	O
)	O

511	O
(	O
42	O
.	O
6	O
)	O

47	O
(	O
43	O
.	O
9	O
)	O

≥	O
60	O

12	O
(	O
7	O
.	O
4	O
)	O

317	O
(	O
26	O
.	O
4	O
)	O

17	O
(	O
15	O
.	O
9	O
)	O

Male	O
,	O
n	O
(%)	O

83	O
(	O
51	O
.	O
6	O
)	O

710	O
(	O
59	O
.	O
2	O
)	O

64	O
(	O
59	O
.	O
8	O
)	O

0	O
.	O
175	O

Needle	O
Sharing	O
Yes	O

22	O
(	O
13	O
.	O
8	O
)	O

517	O
(	O
43	O
.	O
4	O
)	O

46	O
(	O
43	O
.	O
0	O
)	O

<	O
0	O
.	O
001	O

No	O

137	O
(	O
86	O
.	O
2	O
)	O

675	O
(	O
56	O
.	O
6	O
)	O

61	O
(	O
57	O
.	O
0	O
)	O

BMI	O
,	O
kg	O
/	O
m2a	O
(	O
range	O
)	O

24	O
.	O
46	O
(	O
17	O
.	O
09	O
–	O
38	O
.	O
44	O
)	O

23	O
.	O
80	O
(	O
12	O
.	O
91	O
–	O
37	O
.	O
58	O
)	O

23	O
.	O
88	O
(	O
17	O
.	O
63	O
–	O
34	O
.	O
48	O
)	O

0	O
.	O
085	O

HCV	B-OG
genotype	O
,	O
n	O
(%)	O
1b	O

416	O
(	O
49	O
.	O
35	O
)	O

15	O
(	O
45	O
.	O
46	O
)	O

2a	O

283	O
(	O
33	O
.	O
57	O
)	O

11	O
(	O
33	O
.	O
33	O
)	O

0	O
.	O
740	O

1b	O
/	O
2a	O

13	O
(	O
1	O
.	O
54	O
)	O

0	O
(	O
0	O
)	O

Undetermined	O

131	O
(	O
15	O
.	O
54	O
)	O

7	O
(	O
21	O
.	O
21	O
)	O

AST	B-GP
,	O
IU	O
/	O
L	O
(	O
range	O
)	O

27	O
(	O
5	O
–	O
247	O
)	O
▲	O

35	O
(	O
10	O
–	O
494	O
)	O

34	O
(	O
12	O
–	O
154	O
)	O
#	O

<	O
0	O
.	O
001	O

ALT	B-GP
,	O
IU	O
/	O
L	O
(	O
range	O
)	O

25	O
(	O
6	O
–	O
219	O
)	O
▲	O

37	O
(	O
4	O
–	O
607	O
)	O

36	O
(	O
7	O
–	O
173	O
)	O
#	O

<	O
0	O
.	O
001	O

ALP	B-GP
,	O
IU	O
/	O
L	O
(	O
range	O
)	O

74	O
(	O
33	O
–	O
133	O
)	O
▲	O

77	O
(	O
30	O
–	O
750	O
)	O

77	O
(	O
32	O
–	O
205	O
)	O
#	O

0	O
.	O
003	O

GGT	B-GP
,	O
IU	O
/	O
L	O
(	O
range	O
)	O

21	O
(	O
9	O
–	O
437	O
)	O
▲	O

39	O
(	O
9	O
–	O
867	O
)	O

41	O
(	O
8	O
–	O
539	O
)	O
#	O

<	O
0	O
.	O
001	O

TP	O
,	O
g	O
/	O
L	O
(	O
range	O
)	O

76	O
(	O
55	O
.	O
3	O
–	O
122	O
.	O
1	O
)	O
▲	O

77	O
.	O
1	O
(	O
56	O
.	O
3	O
–	O
104	O
.	O
2	O
)	O

75	O
.	O
3	O
(	O
64	O
.	O
6	O
–	O
92	O
.	O
8	O
)	O
#	O

0	O
.	O
013	O

ALB	B-GP
,	O
g	O
/	O
L	O
(	O
range	O
)	O

45	O
.	O
7	O
(	O
29	O
.	O
5	O
–	O
56	O
)	O
▲	O

44	O
.	O
9	O
(	O
28	O
.	O
4	O
–	O
62	O
.	O
3	O
)	O

44	O
.	O
5	O
(	O
33	O
.	O
4	O
–	O
57	O
.	O
2	O
)	O
#	O

0	O
.	O
005	O

GLB	B-GP
,	O
g	O
/	O
L	O
(	O
range	O
)	O

29	O
.	O
7	O
(	O
20	O
.	O
9	O
–	O
48	O
.	O
9	O
)	O
▲	O

31	O
.	O
75	O
(	O
19	O
.	O
3	O
–	O
52	O
.	O
5	O
)	O

31	O
.	O
4	O
(	O
20	O
.	O
6	O
–	O
49	O
.	O
9	O
)	O
#	O

<	O
0	O
.	O
001	O

TBIL	O
,	O
μmol	O
/	O
L	O
(	O
range	O
)	O

12	O
.	O
95	O
(	O
3	O
.	O
4	O
–	O
41	O
.	O
5	O
)	O

13	O
.	O
5	O
(	O
3	O
–	O
299	O
.	O
5	O
)	O

13	O
.	O
25	O
(	O
4	O
.	O
2	O
–	O
68	O
.	O
5	O
)	O

0	O
.	O
967	O

DBIL	O
,	O
μmol	O
/	O
L	O
(	O
range	O
)	O

3	O
.	O
85	O
(	O
1	O
.	O
2	O
–	O
13	O
.	O
9	O
)	O

4	O
.	O
3	O
(	O
0	O
.	O
3	O
–	O
248	O
.	O
4	O
)	O

4	O
.	O
2	O
(	O
1	O
.	O
9	O
–	O
26	O
.	O
4	O
)	O

0	O
.	O
039	O

IBIL	O
,	O
μmol	O
/	O
L	O
(	O
range	O
)	O

9	O
.	O
3	O
(	O
1	O
.	O
4	O
–	O
34	O
.	O
4	O
)	O

9	O
.	O
2	O
(	O
1	O
.	O
5	O
–	O
51	O
.	O
1	O
)	O

9	O
.	O
3	O
(	O
2	O
.	O
1	O
–	O
42	O
.	O
1	O
)	O

0	O
.	O
644	O

CHE	B-GP
,	O
IU	O
/	O
L	O
(	O
range	O
)	O

8489	O
.	O
5	O
(	O
1446	O
–	O
26421	O
)	O
▲	O

8072	O
(	O
546	O
–	O
16877	O
)	O
*	O

7239	O
(	O
1623	O
–	O
15890	O
)	O
#	O

0	O
.	O
007	O

BUN	O
,	O
mmol	O
/	O
L	O
(	O
range	O
)	O

5	O
.	O
24	O
(	O
2	O
.	O
53	O
–	O
12	O
.	O
39	O
)	O
▲	O

5	O
.	O
53	O
(	O
1	O
.	O
64	O
–	O
11	O
.	O
86	O
)	O

5	O
.	O
48	O
(	O
2	O
.	O
7	O
–	O
9	O
.	O
29	O
)	O

0	O
.	O
036	O

Cr	O
,	O
μmol	O
/	O
L	O
(	O
range	O
)	O

65	O
.	O
2	O
(	O
42	O
–	O
108	O
)	O

66	O
.	O
6	O
(	O
31	O
–	O
171	O
)	O

65	O
(	O
38	O
.	O
1	O
–	O
120	O
)	O

0	O
.	O
351	O

TG	O
,	O
mmol	O
/	O
L	O
(	O
range	O
)	O

1	O
.	O
3	O
(	O
0	O
.	O
4	O
–	O
16	O
.	O
31	O
)	O

1	O
.	O
3	O
(	O
0	O
.	O
34	O
–	O
19	O
.	O
43	O
)	O

1	O
.	O
24	O
(	O
0	O
.	O
5	O
–	O
12	O
.	O
5	O
)	O

0	O
.	O
768	O

TC	O
,	O
mmol	O
/	O
L	O
(	O
range	O
)	O

4	O
.	O
6	O
(	O
2	O
.	O
75	O
–	O
8	O
.	O
95	O
)	O

4	O
.	O
5	O
(	O
2	O
.	O
11	O
–	O
10	O
.	O
58	O
)	O

4	O
.	O
44	O
(	O
2	O
.	O
8	O
–	O
10	O
.	O
4	O
)	O

0	O
.	O
383	O

GLU	O
,	O
mmol	O
/	O
L	O
(	O
range	O
)	O

4	O
.	O
1	O
(	O
2	O
.	O
24	O
–	O
13	O
.	O
12	O
)	O

4	O
.	O
17	O
(	O
1	O
.	O
51	O
–	O
28	O
.	O
28	O
)	O

3	O
.	O
98	O
(	O
2	O
.	O
69	O
–	O
13	O
.	O
31	O
)	O

0	O
.	O
097	O

PLT	O
10	O
^	O
9	O
/	O
L	O
(	O
range	O
)	O

202	O
(	O
49	O
–	O
336	O
)	O
▲	O

185	O
.	O
5	O
(	O
30	O
–	O
390	O
)	O

180	O
(	O
62	O
–	O
377	O
)	O
#	O

0	O
.	O
041	O

APRI	O
level	O
(	O
mean	O
±	O
SD	O
)	O

0	O
.	O
2	O
±	O
0	O
.	O
24	O
▲	O

0	O
.	O
34	O
±	O
0	O
.	O
44	O

0	O
.	O
3	O
±	O
0	O
.	O
34	O

<	O
0	O
.	O
001	O

FIB	O
-	O
4	O
level	O
(	O
mean	O
±	O
SD	O
)	O

1	O
.	O
58	O
±	O
1	O
.	O
14	O
▲	O

2	O
.	O
39	O
±	O
2	O
.	O
15	O

2	O
.	O
3	O
±	O
1	O
.	O
88	O
#	O

<	O
0	O
.	O
001	O

HCV	B-OG
viral	O
genotype	O
was	O
not	O
available	O
for	O
357	O
individuals	O
in	O
the	O
HCV	B-OG
mono	O
-	O
infection	B-DS
group	O
and	O
74	O
individuals	O
in	O
the	O
HCV	B-OG
-	O
HBV	B-OG
co	B-DS
-	I-DS
infection	I-DS
group	O
;	O
however	O
,	O
those	O
with	O
undetermined	O
genotype	O
results	O
were	O
not	O
among	O
the	O
treated	O
patients	O
.	O

▲	O
P	O
<	O
0	O
.	O
05	O
,	O
HBV	B-OG
versus	O
HCV	B-OG
group	O

*	O
P	O
<	O
0	O
.	O
05	O
,	O
HCV	B-OG
versus	O
HBV	B-OG
-	O
HCV	B-OG
group	O

#	O
P	O
<	O
0	O
.	O
05	O
,	O
HBV	B-OG
versus	O
HBV	B-OG
-	O
HCV	B-OG
group	O

Quantitative	O
variables	O
are	O
displayed	O
as	O
interquartile	O
range	O
(	O
range	O
),	O
except	O
age	O
.	O
APRI	O
and	O
FIB	O
-	O
4	O
level	O
which	O
are	O
displayed	O
as	O
mean	O
±	O
SD	O
BMI	O
,	O
body	O
mass	O
index	O
;	O
ALT	B-GP
,	O
alanine	B-GP
aminotransferase	I-GP
,	O
Normal	O
value	O
:	O
8	O
–	O
50	O
.	O
00	O
U	O
/	O
L	O
;	O
AST	B-GP
,	O
aspartate	B-GP
aminotransferase	I-GP
,	O
Normal	O
value	O
:	O
8	O
–	O
40	O
.	O
00	O
U	O
/	O
L	O
;	O
ALP	B-GP
,	O
alkaline	B-GP
phosphatase	I-GP
,	O
Normal	O
value	O
:	O
15	O
–	O
112	O
.	O
00	O
U	O
/	O
L	O
;	O
GGT	B-GP
,	O
glutamyl	B-GP
transpeptidase	I-GP
,	O
Normal	O
value	O
:	O
5	O
–	O
54	O
.	O
00	O
U	O
/	O
L	O
;	O
TP	O
,	O
total	O
protein	O
,	O
Normal	O
value	O
:	O
60	O
–	O
83	O
.	O
00	O
g	O
/	O
l	O
;	O
ALB	B-GP
,	O
albumin	B-GP
,	O
Normal	O
value	O
:	O
35	O
–	O
55	O
.	O
00	O
g	O
/	O
l	O
;	O
GLB	B-GP
,	O
globulin	B-GP
,	O
Normal	O
value	O
:	O
20	O
–	O
30	O
.	O
00	O
g	O
/	O
L	O
;	O
TBIL	O
,	O
total	O
bilirubin	O
,	O
Normal	O
value	O
:	O
6	O
.	O
8	O
–	O
30	O
.	O
00	O
μmol	O
/	O
L	O
;	O
DBIL	O
,	O
direct	O
bilirubin	O
,	O
Normal	O
value	O
:	O
0	O
–	O
8	O
.	O
60	O
μmol	O
/	O
L	O
;	O
IBIL	O
,	O
indirect	O
bilirubin	O
,	O
Normal	O
value	O
:	O
5	O
.	O
1	O
–	O
21	O
.	O
40	O
umol	O
/	O
L	O
;	O
CHE	B-GP
,	O
cholinesterase	B-GP
,	O
Normal	O
value	O
:	O
4300	O
–	O
12000	O
.	O
00	O
U	O
/	O
L	O
;	O
BUN	O
,	O
blood	O
urea	O
nitrogen	O
,	O
Normal	O
value	O
:	O
3	O
.	O
2	O
–	O
7	O
.	O
00	O
mmol	O
/	O
L	O
;	O
Cr	O
,	O
creatinine	O
,	O
Normal	O
value	O
:	O
44	O
–	O
115	O
.	O
00	O
μmol	O
/	O
L	O
;	O
TG	O
,	O
triglycerides	O
,	O
Normal	O
value	O
:	O
0	O
.	O
28	O
–	O
1	O
.	O
80	O
mmol	O
/	O
L	O
;	O
TC	O
,	O
total	O
cholesterol	O
,	O
Normal	O
value	O
:	O
2	O
.	O
6	O
–	O
6	O
.	O
00	O
mmol	O
/	O
L	O
;	O
GLU	O
,	O
glucose	O
,	O
Normal	O
value	O
:	O
3	O
.	O
9	O
–	O
6	O
.	O
10	O
mmol	O
/	O
L	O
;	O
PLT	O
,	O
platelet	O
,	O
Normal	O
value	O
:	O
100	O
–	O
300	O
.	O
00	O
10	O
^	O
9	O
/	O
L	O
;	O
APRI	O
,	O
aspartate	B-GP
aminotransferase	I-GP
to	O
platelet	O
ratio	O
index	O
;	O
FIB	O
-	O
4	O
,	O
fibrosis	O
index	O
based	O
on	O
the	O
four	O
factors	O
score	O

Raimondo	O
et	O
al	O
.	O
previously	O
defined	O
the	O
following	O
four	O
patterns	O
of	O
viral	O
dominance	O
in	O
HBV	B-OG
-	O
HCV	B-OG
co	O
-	O
infected	O
patients	O
[	O
7	O
]:	O
Group	O
(	O
a	O
)	O
HCV	B-OG
dominance	O
with	O
HCV	B-OG
RNA	O
>	O
15	O
IU	O
/	O
mL	O
and	O
HBV	B-OG
DNA	O
<	O
2000	O
IU	O
/	O
mL	O
;	O
Group	O
(	O
b	O
)	O
both	O
viruses	B-OG
dominant	O
with	O
HBV	B-OG
DNA	O
>	O
2000	O
IU	O
/	O
mL	O
and	O
HCV	B-OG
RNA	O
>	O
15	O
IU	O
/	O
mL	O
;	O
Group	O
(	O
c	O
)	O
HBV	B-OG
dominance	O
with	O
HBV	B-OG
DNA	O
>	O
2000	O
IU	O
/	O
mL	O
and	O
HCV	B-OG
RNA	O
<	O
15IU	O
/	O
mL	O
;	O
and	O
Group	O
(	O
d	O
)	O
no	O
virus	B-OG
dominant	O
with	O
HBV	B-OG
DNA	O
<	O
2000	O
IU	O
/	O
mL	O
and	O
HCV	B-OG
RNA	O
<	O
15	O
IU	O
/	O
mL	O
.	O

The	O
mean	O
age	O
of	O
patients	O
in	O
HBV	B-OG
mono	O
-	O
infection	B-DS
(	O
46	O
.	O
5	O
years	O
)	O
was	O
lower	O
than	O
patients	O
with	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
(	O
52	O
.	O
1	O
years	O
)	O
and	O
HCV	B-OG
mono	O
-	O
infection	B-DS
(	O
54	O
.	O
2	O
years	O
),	O
but	O
the	O
age	O
of	O
patients	O
with	O
HCV	B-OG
mono	O
-	O
infection	B-DS
was	O
higher	O
than	O
in	O
patients	O
with	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
(	O
Table	O
1	O
).	O

No	O
difference	O
in	O
the	O
prevalence	O
of	O
males	O
was	O
observed	O
among	O
the	O
different	O
groups	O
.	O

However	O
,	O
there	O
was	O
significantly	O
fewer	O
patients	O
who	O
shared	O
contaminated	O
needles	O
in	O
the	O
HBV	B-OG
mono	O
-	O
infected	O
group	O
(	O
13	O
.	O
8	O
%)	O
compared	O
to	O
the	O
HCV	B-OG
mono	O
-	O
infected	O
(	O
43	O
.	O
4	O
%)	O
and	O
HBV	B-OG
-	O
HCV	B-OG
co	O
-	O
infected	O
(	O
43	O
.	O
0	O
%)	O
groups	O
(	O
P	O
<	O
0	O
.	O
001	O
;	O
Table	O
1	O
).	O

Comparison	O
of	O
Virological	O
Characteristics	O
between	O
Patients	O
with	O
HBV	B-OG
-	O
HCV	B-OG
Co	B-DS
-	I-DS
Infection	I-DS
and	O
HCV	B-OG
Mono	O
-	O
Infection	B-DS

Previous	O
reports	O
have	O
demonstrated	O
that	O
approximately	O
15	O
%-	O
45	O
%	O
of	O
patients	O
infected	O
with	O
HCV	B-OG
spontaneously	O
clear	O
the	O
virus	B-OG
[	O
20	O
–	O
24	O
].	O

In	O
this	O
investigation	O
,	O
13	O
.	O
1	O
%	O
of	O
patients	O
with	O
HCV	B-OG
mono	O
-	O
infection	B-DS
were	O
negative	O
for	O
HCV	B-OG
RNA	O
,	O
while	O
up	O
to	O
46	O
.	O
7	O
%	O
of	O
patients	O
with	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
had	O
undetectable	O
HCV	B-OG
RNA	O
(	O
P	O
<	O
0	O
.	O
001	O
,	O
Table	O
2	O
).	O

Comparison	O
of	O
serum	O
viral	O
Loads	O
and	O
HBsAg	B-GP
levels	O
.	O

HBV	B-OG

HCV	B-OG

HBV	B-OG
-	O
HCV	B-OG

Variable	O

N	O
=	O
161	O

N	O
=	O
1200	O

N	O
=	O
107	O

P	O
Value	O

Serum	O
HCV	B-OG
-	O
RNA	O

Positive	O
,	O
n	O
(%)	O

none	O

1043	O
(	O
86	O
.	O
9	O
)	O

57	O
(	O
53	O
.	O
3	O
)	O

6	O
.	O
59E	O
-	O
20	O

Negative	O
,	O
n	O
(%)	O

nne	O

157	O
(	O
13	O
.	O
1	O
)	O

50	O
(	O
46	O
.	O
7	O
)	O

<	O
4	O
×	O
105	O
IU	O
/	O
ml	O

none	O

52243	O
.	O
5	O
)	O

82	O
(	O
76	O
.	O
6	O
)	O

5	O
.	O
93E	O
-	O
11	O

≥	O
4	O
×	O
105	O
IU	O
/	O
ml	O

none	O

678	O
(	O
56	O
.	O
5	O
)	O

25	O
(	O
23	O
.	O
4	O
)	O

Serum	O
HBV	B-OG
-	O
DNA	O

Positive	O
,	O
n	O
(%)	O

152	O
(	O
94	O
.	O
4	O
)	O

none	O

90	O
(	O
84	O
.	O
1	O
)	O

2	O
.	O
21E	O
-	O
26	O

Negative	O
,	O
n	O
(%)	O

9	O
(	O
5	O
.	O
6	O
)	O

none	O

17	O
(	O
15	O
.	O
9	O
)	O

HCV	B-OG
load	O
,	O
log10	O
IU	O
/	O
mL	O
(	O
IQR	O
)	O

None	O

5	O
.	O
87	O
(	O
3	O
.	O
54	O
–	O
6	O
.	O
71	O
)	O

1	O
.	O
18	O
(	O
0	O
–	O
5	O
.	O
57	O
)	O

1	O
.	O
60E	O
-	O
17	O

HBV	B-OG
load	O
,	O
log10	O
IU	O
/	O
mL	O
(	O
IQR	O
)	O

3	O
.	O
06	O
(	O
2	O
–	O
4	O
.	O
28	O
)	O

none	O

1	O
.	O
97	O
(	O
1	O
.	O
3	O
–	O
3	O
.	O
43	O
)	O

3	O
.	O
68E	O
-	O
14	O

Serum	O
HBeAg	B-GP

Positive	O
,	O
n	O
(%)	O

35	O
(	O
21	O
.	O
7	O
)	O

none	O

7	O
(	O
6	O
.	O
5	O
)	O

1	O
.	O
02E	O
-	O
52	O

Negative	O
,	O
n	O
(%)	O

126	O
(	O
78	O
.	O
3	O
)	O

none	O

100	O
(	O
93	O
.	O
5	O
)	O

Serum	O
HBsAg	B-GP
level	O
(	O
COI	O
)	O

<	O
0	O
.	O
0001	O

<	O
1000	O
,	O
n	O
(%)	O

33	O
(	O
20	O
.	O
5	O
)	O

none	O

47	O
(	O
43	O
.	O
92	O
)	O

<	O
0	O
.	O
0001	O

1000	O
–	O
4000	O
,	O
n	O
(%)	O

38	O
(	O
23	O
.	O
6	O
)	O

none	O

8	O
(	O
7	O
.	O
48	O
)	O

0	O
.	O
0006	O

>	O
4000	O
,	O
n	O
(%)	O

90	O
(	O
55	O
.	O
9	O
)	O

none	O

52	O
(	O
48	O
.	O
6	O
)	O

0	O
.	O
2408	O

COI	O
,	O
cutoff	O
index	O

The	O
median	O
HCV	B-OG
RNA	O
levels	O
of	O
HBV	B-OG
-	O
HCV	B-OG
co	O
-	O
infected	O
patients	O
was	O
significantly	O
lower	O
than	O
those	O
of	O
mono	O
-	O
infected	O
HCV	B-OG
patients	O
,	O
(	O
1	O
.	O
18	O
[	O
Interquartile	O
range	O
(	O
IQR	O
)	O
0	O
–	O
5	O
.	O
57	O
]	O
versus	O
5	O
.	O
87	O
[	O
IQR	O
,	O
3	O
.	O
54	O
–	O
6	O
.	O
71	O
]	O
Log10	O
IU	O
/	O
ml	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
as	O
was	O
the	O
percentage	O
of	O
patients	O
with	O
HCV	B-OG
RNA	O
level	O
≥	O
4	O
×	O
105	O
IU	O
/	O
mL	O
(	O
23	O
.	O
4	O
%	O
versus	O
56	O
.	O
5	O
%,	O
P	O
<	O
0	O
.	O
001	O
)	O
(	O
Table	O
2	O
).	O

We	O
then	O
repeated	O
this	O
analysis	O
,	O
excluding	O
anti	O
-	O
HCV	B-OG
positive	O
patients	O
without	O
viremia	B-DS
(	O
HCV	B-OG
RNA	O
negative	O
).	O

We	O
found	O
the	O
median	O
HCV	B-OG
RNA	O
levels	O
of	O
co	O
-	O
infected	O
patients	O
(	O
5	O
.	O
19	O
[	O
IQR	O
,	O
1	O
.	O
79	O
–	O
6	O
.	O
25	O
]	O
Log10	O
IU	O
/	O
mL	O
)	O
were	O
still	O
significantly	O
lower	O
than	O
those	O
of	O
HCV	B-OG
mono	O
-	O
infected	O
patients	O
(	O
6	O
.	O
10	O
[	O
IQR	O
,	O
4	O
.	O
95	O
–	O
6	O
.	O
79	O
]	O
Log10	O
IU	O
/	O
ml	O
;	O
P	O
<	O
0	O
.	O
001	O
).	O

We	O
then	O
excluded	O
HCV	B-OG
core	B-GP
Ag	I-GP
negative	O
(	O
HCV	B-OG
core	B-GP
Ag	I-GP
<	O
3fmol	O
/	O
L	O
)	O
or	O
anti	O
-	O
HCV	B-OG
positive	O
patients	O
without	O
viremia	B-DS
(	O
HCV	B-OG
RNA	O
viral	O
negative	O
);	O
88	O
and	O
42	O
patients	O
were	O
included	O
in	O
the	O
HCV	B-OG
mono	O
-	O
infection	B-DS
and	O
co	B-DS
-	I-DS
infection	I-DS
groups	O
,	O
respectively	O
(	O
Table	O
3	O
).	O

Again	O
,	O
the	O
mean	O
HCV	B-OG
RNA	O
levels	O
were	O
significantly	O
lower	O
in	O
the	O
co	O
-	O
infected	O
group	O
(	O
5	O
.	O
40	O
±	O
1	O
.	O
42	O
Log10	O
IU	O
/	O
mL	O
)	O
than	O
in	O
the	O
HCV	B-OG
mono	O
-	O
infection	B-DS
group	O
(	O
5	O
.	O
95	O
±	O
1	O
.	O
30	O
Log10	O
IU	O
/	O
ml	O
;	O
P	O
=	O
0	O
.	O
033	O
).	O

Comparison	O
of	O
serum	O
HCV	B-OG
core	B-GP
Ag	I-GP
levels	O
and	O
scores	O
of	O
the	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
and	O
matched	O
HCV	B-OG
controls	O
.	O

HCV	B-OG
+	O
HBsAg	B-GP

HCV	B-OG

HCV	B-OG
+	O
HBsAg	B-GP
(	O
HCV	B-OG
-	O
RNA	O
-	O
positive	O
)	O

HCV	B-OG
(	O
HCV	B-OG
-	O
RNA	O
-	O
positive	O
)	O

Variable	O

N	O
=	O
107	O

N	O
=	O
107	O

P	O
Value	O

N	O
=	O
57	O

N	O
=	O
98	O

P	O
Value	O

Serum	O
HCV	B-OG
core	B-GP
Ag	I-GP

Positive	O
,	O
n	O
(%)	O

56	O
(	O
52	O
.	O
34	O
)	O

78	O
(	O
72	O
.	O
90	O
)	O

42	O
(	O
73	O
.	O
68	O
)	O

88	O
(	O
89	O
.	O
80	O
)	O

Negative	O
,	O
n	O
(%)	O

51	O
(	O
47	O
.	O
66	O
)	O

29	O
(	O
27	O
.	O
10	O
)	O

0	O
.	O
0019	O

15	O
(	O
26	O
.	O
32	O
)	O

10	O
(	O
10	O
.	O
20	O
)	O

0	O
.	O
0085	O

HCV	B-OG
core	B-GP
Ag	I-GP
level	O
(	O
fmol	O
/	O
L	O
)(	O
IQR	O
)	O

3	O
.	O
14	O
(	O
2	O
.	O
09	O
–	O
832	O
.	O
0	O
)	O

1830	O
(	O
33	O
.	O
26	O
–	O
4516	O
)	O

<	O
0	O
.	O
0001	O

661	O
.	O
6	O
(	O
2	O
.	O
8	O
–	O
5099	O
.	O
1	O
)	O

2141	O
.	O
3	O
(	O
348	O
.	O
0	O
–	O
5039	O
.	O
7	O
)	O

0	O
.	O
047	O

APRI	O
level	O
(	O
IQR	O
)	O

0	O
.	O
20	O
(	O
0	O
.	O
11	O
–	O
0	O
.	O
37	O
)	O

0	O
.	O
17	O
(	O
0	O
.	O
11	O
–	O
0	O
.	O
37	O
)	O

0	O
.	O
5443	O

0	O
.	O
21	O
(	O
0	O
.	O
14	O
–	O
0	O
.	O
34	O
)	O

0	O
.	O
20	O
(	O
0	O
.	O
123	O
–	O
0	O
.	O
34	O
)	O

0	O
.	O
724	O

FIB	O
-	O
4	O
level	O
(	O
IQR	O
)	O

1	O
.	O
73	O
(	O
1	O
.	O
24	O
–	O
2	O
.	O
89	O
)	O

1	O
.	O
61	O
(	O
1	O
.	O
13	O
–	O
2	O
.	O
27	O
)	O

0	O
.	O
1623	O

1	O
.	O
92	O
(	O
1	O
.	O
27	O
–	O
2	O
.	O
97	O
)	O

1	O
.	O
66	O
(	O
1	O
.	O
19	O
–	O
2	O
.	O
31	O
)	O

0	O
.	O
327	O

To	O
test	O
whether	O
patients	O
with	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
have	O
a	O
lower	O
level	O
of	O
HCV	B-OG
core	B-GP
Ag	I-GP
compared	O
to	O
patients	O
with	O
HCV	B-OG
mono	O
-	O
infection	B-DS
,	O
we	O
measured	O
HCV	B-OG
core	B-GP
Ag	I-GP
levels	O
in	O
the	O
107	O
HBV	B-OG
-	O
HCV	B-OG
patients	O
and	O
in	O
107	O
age	O
-	O
and	O
gender	O
-	O
matched	O
patients	O
with	O
HCV	B-OG
mono	O
-	O
infection	B-DS
.	O

Similar	O
to	O
the	O
HCV	B-OG
RNA	O
findings	O
,	O
the	O
percentage	O
of	O
HCV	B-OG
core	B-GP
Ag	I-GP
-	O
positive	O
patients	O
was	O
significantly	O
lower	O
in	O
the	O
HBV	B-OG
-	O
HCV	B-OG
co	O
-	O
infected	O
group	O
than	O
in	O
the	O
HCV	B-OG
mono	O
-	O
infected	O
group	O
(	O
52	O
.	O
34	O
%	O
versus	O
72	O
.	O
90	O
%,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
as	O
were	O
the	O
mean	O
HCV	B-OG
core	B-GP
Ag	I-GP
levels	O
(	O
3	O
.	O
14	O
[	O
IQR	O
,	O
2	O
.	O
09	O
–	O
832	O
.	O
0	O
]	O
versus	O
1830	O
[	O
IQR	O
,	O
33	O
.	O
26	O
–	O
4516	O
],	O
respectively	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
(	O
Table	O
3	O
).	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
percentage	O
of	O
HCV	B-OG
core	B-GP
Ag	I-GP
-	O
positive	O
patients	O
between	O
the	O
HBV	B-OG
DNA	O
-	O
negative	O
/	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
group	O
and	O
the	O
HBV	B-OG
DNA	O
-	O
positive	O
/	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
group	O
(	O
58	O
.	O
82	O
%	O
versus	O
51	O
.	O
11	O
%,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
559	O
)	O
(	O
Table	O
4	O
);	O
nor	O
was	O
there	O
a	O
significant	O
difference	O
in	O
mean	O
HCV	B-OG
core	B-GP
Ag	I-GP
levels	O
between	O
these	O
two	O
groups	O
(	O
1760	O
±	O
2970	O
versus	O
1434	O
±	O
3095	O
mean	O
±	O
SD	O
;	O
P	O
=	O
0	O
.	O
509	O
).	O

There	O
percentage	O
of	O
HCV	B-OG
core	B-GP
Ag	I-GP
-	O
positive	O
patients	O
in	O
the	O
HCV	B-OG
RNA	O
-	O
negative	O
/	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
group	O
was	O
significantly	O
lower	O
than	O
in	O
the	O
HCV	B-OG
RNA	O
-	O
positive	O
/	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
group	O
(	O
28	O
.	O
0	O
%	O
versus	O
73	O
.	O
68	O
%,	O
P	O
<	O
0	O
.	O
0001	O
)	O
(	O
Table	O
4	O
).	O

There	O
was	O
also	O
a	O
significant	O
difference	O
in	O
mean	O
HCV	B-OG
core	B-GP
Ag	I-GP
levels	O
between	O
these	O
two	O
groups	O
(	O
3	O
.	O
576	O
±	O
5	O
.	O
906	O
versus	O
2785	O
±	O
3753	O
mean	O
±	O
SD	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
(	O
Table	O
4	O
).	O

Comparison	O
of	O
serum	O
HCV	B-OG
core	B-GP
Ag	I-GP
levels	O
in	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
patients	O
.	O

HBV	B-OG
DNA	O
-	O
negative	O

HBV	B-OG
DNA	O
-	O
positive	O

HCV	B-OG
RNA	O
-	O
negative	O

HCV	B-OG
RNA	O
-	O
positive	O

Variable	O

N	O
=	O
17	O

N	O
=	O
90	O

P	O
Value	O

N	O
=	O
50	O

N	O
=	O
57	O

P	O
Value	O

Serum	O
HCV	B-OG
core	B-GP
Ag	I-GP

Positive	O
,	O
n	O
(%)	O

10	O
(	O
58	O
.	O
82	O
)	O

46	O
(	O
51	O
.	O
11	O
)	O

14	O
(	O
28	O
.	O
0	O
)	O

42	O
(	O
73	O
.	O
68	O
)	O

Negative	O
,	O
n	O
(%)	O

7	O
(	O
41	O
.	O
18	O
)	O

44	O
(	O
48	O
.	O
89	O
)	O

0	O
.	O
5593	O

36	O
(	O
72	O
.	O
0	O
)	O

15	O
(	O
26	O
.	O
32	O
)	O

<	O
0	O
.	O
0001	O

HCV	B-OG
core	B-GP
Ag	I-GP
level	O
,	O
(	O
fmol	O
/	O
L	O
)(	O
mean	O
±	O
SD	O
)	O

1760	O
±	O
2970	O

1434	O
±	O
3095	O

0	O
.	O
509	O

3	O
.	O
576	O
±	O
5	O
.	O
906	O

2785	O
±	O
3753	O

<	O
0	O
.	O
0001	O

HCV	B-OG
genotyping	O
was	O
performed	O
in	O
876	O
HCV	B-OG
RNA	O
-	O
positive	O
patients	O
.	O

HCV	B-OG
genotype	O
1b	O
was	O
detected	O
in	O
431	O
patients	O
(	O
49	O
.	O
20	O
%),	O
genotype	O
2a	O
was	O
detected	O
in	O
294	O
patients	O
(	O
33	O
.	O
56	O
%),	O
and	O
genotype	O
1b	O
/	O
2a	O
was	O
detected	O
in	O
13	O
patients	O
(	O
1	O
.	O
49	O
%).	O

We	O
were	O
unable	O
to	O
determine	O
the	O
HCV	B-OG
genotype	O
in	O
138	O
patients	O
(	O
15	O
.	O
75	O
%).	O

The	O
distribution	O
of	O
HCV	B-OG
genotypes	O
did	O
not	O
differ	O
between	O
the	O
HBV	B-OG
-	O
HCV	B-OG
co	O
-	O
infected	O
patients	O
and	O
the	O
HCV	B-OG
mono	O
-	O
infected	O
patients	O
(	O
P	O
=	O
0	O
.	O
740	O
).	O

The	O
HBV	B-OG
-	O
HCV	B-OG
co	O
-	O
infected	O
group	O
had	O
similar	O
ALT	B-GP
,	O
AST	B-GP
,	O
ALP	B-GP
,	O
GGT	B-GP
,	O
ALB	B-GP
,	O
total	O
platelet	O
,	O
APRI	O
,	O
and	O
FIB	O
-	O
4	O
levels	O
compared	O
to	O
those	O
of	O
the	O
HCV	B-OG
mono	O
-	O
infected	O
group	O
(	O
Table	O
1	O
).	O

We	O
found	O
no	O
significant	O
differences	O
in	O
APRI	O
and	O
FIB	O
-	O
4	O
levels	O
between	O
the	O
107	O
HBV	B-OG
-	O
HCV	B-OG
co	O
-	O
infected	O
patients	O
and	O
107	O
matched	O
HCV	B-OG
controls	O
,	O
or	O
between	O
these	O
two	O
groups	O
of	O
patients	O
with	O
HCV	B-OG
RNA	O
viremia	B-DS
.	O

(	O
Table	O
3	O
).	O

Comparison	O
of	O
Virological	O
Characteristics	O
between	O
Patients	O
with	O
HBV	B-OG
-	O
HCV	B-OG
Co	B-DS
-	I-DS
Infection	I-DS
and	O
HBV	B-OG
Mono	O
-	O
Infection	B-DS

The	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
group	O
had	O
a	O
lower	O
percentage	O
of	O
HBV	B-OG
DNA	O
positive	O
patients	O
compared	O
to	O
that	O
of	O
the	O
HBV	B-OG
mono	O
-	O
infection	B-DS
group	O
(	O
84	O
.	O
1	O
%	O
versus	O
94	O
.	O
4	O
%,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
(	O
Table	O
2	O
).	O

In	O
addition	O
,	O
the	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
group	O
had	O
significantly	O
lower	O
median	O
HBV	B-OG
DNA	O
levels	O
than	O
those	O
of	O
the	O
HBV	B-OG
mono	O
-	O
infection	B-DS
group	O
(	O
1	O
.	O
97	O
[	O
IQR	O
,	O
1	O
.	O
3	O
–	O
3	O
.	O
43	O
]	O
versus	O
3	O
.	O
06	O
[	O
IQR	O
,	O
2	O
–	O
4	O
.	O
28	O
]	O
Log10	O
IU	O
/	O
mL	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
001	O
).	O

Furthermore	O
,	O
6	O
.	O
5	O
%	O
(	O
7	O
/	O
107	O
)	O
of	O
patients	O
with	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
had	O
undetectable	O
HBV	B-OG
DNA	O
and	O
HCV	B-OG
RNA	O
levels	O
.	O

The	O
percentage	O
of	O
HBeAg	B-GP
-	O
positive	O
patients	O
in	O
the	O
HBV	B-OG
mono	O
-	O
infection	B-DS
group	O
was	O
21	O
.	O
7	O
%	O
(	O
35	O
/	O
161	O
),	O
which	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
co	B-DS
-	I-DS
infection	I-DS
group	O
[	O
6	O
.	O
5	O
%	O
(	O
7	O
/	O
107	O
);	O
P	O
<	O
0	O
.	O
0001	O
;	O
Table	O
2	O
].	O

The	O
percentage	O
of	O
patients	O
with	O
HBsAg	B-GP
levels	O
less	O
than	O
1000	O
cutoff	O
index	O
in	O
the	O
co	B-DS
-	I-DS
infection	I-DS
group	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
HBV	B-OG
mono	O
-	O
infection	B-DS
group	O
(	O
43	O
.	O
92	O
%	O
versus	O
20	O
.	O
5	O
%,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
001	O
,	O
Table	O
2	O
).	O

The	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
group	O
had	O
higher	O
ALT	B-GP
,	O
AST	B-GP
,	O
ALP	B-GP
,	O
GGT	B-GP
,	O
APRI	O
and	O
FIB	O
-	O
4	O
levels	O
,	O
but	O
lower	O
ALB	B-GP
and	O
total	O
platelet	O
compared	O
to	O
the	O
HBV	B-OG
mono	O
-	O
infection	B-DS
group	O
(	O
Table	O
1	O
).	O

Baseline	O
Characteristics	O
of	O
HBV	B-OG
and	O
HCV	B-OG
Replication	O
in	O
Patients	O
with	O
HBV	B-OG
-	O
HCV	B-OG
Co	B-DS
-	I-DS
Infection	I-DS

Baseline	O
characteristics	O
of	O
HBV	B-OG
/	O
HCV	B-OG
patients	O
are	O
presented	O
in	O
Table	O
5	O
.	O

Active	O
infection	B-DS
with	O
HBV	B-OG
and	O
HCV	B-OG
was	O
found	O
in	O
8	O
cases	O
,	O
inactive	O
infection	B-DS
by	O
both	O
viruses	B-OG
in	O
40	O
cases	O
,	O
active	O
HBV	B-OG
/	O
inactive	O
HCV	B-OG
in	O
20	O
cases	O
,	O
and	O
inactive	O
HBV	B-OG
/	O
active	O
HCV	B-OG
in	O
39	O
cases	O
.	O

Baseline	O
characteristics	O
of	O
HBV	B-OG
/	O
HCV	B-OG
replication	O
with	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
.	O

HCV	B-OG
+	O
HBV	B-OG
(	O
N	O
=	O
107	O
)	O

a	O
)	O
InactiveHBV	O
/	O
Active	O
HCV	B-OG

b	O
)	O
ActiveHBV	O
/	O
HCV	B-OG

c	O
)	O
ActiveHBV	O
/	O
InactiveHCV	O

d	O
)	O
Inactive	O
HBV	B-OG
/	O
HCV	B-OG

Characteristic	O

(	O
N	O
=	O
39	O
)	O

(	O
N	O
=	O
8	O
)	O

(	O
N	O
=	O
20	O
)	O

(	O
N	O
=	O
40	O
)	O

P	O
Value	O

Age	O
(	O
years	O
),	O
(	O
mean	O
±	O
SD	O
)	O

53	O
.	O
03	O
±	O
6	O
.	O
8	O

51	O
.	O
13	O
±	O
9	O
.	O
88	O

50	O
.	O
85	O
±	O
6	O
.	O
51	O

52	O
.	O
05	O
±	O
7	O
.	O
68	O

0	O
.	O
719	O

Male	O
,	O
n	O
(%)	O

25	O
(	O
64	O
.	O
1	O
)	O

5	O
(	O
62	O
.	O
5	O
)	O

15	O
(	O
75	O
)	O

19	O
(	O
47	O
.	O
5	O
)	O

0	O
.	O
190	O

BMI	O
,	O
kg	O
/	O
m2a	O
(	O
mean	O
±	O
SD	O
)	O

24	O
.	O
17	O
±	O
3	O
.	O
93	O

24	O
.	O
17	O
±	O
3	O
.	O
7	O

24	O
.	O
3	O
±	O
3	O
.	O
14	O

24	O
.	O
84	O
±	O
3	O
.	O
85	O

0	O
.	O
868	O

HCV	B-OG
RNA	O
,	O
log10	O
IU	O
/	O
mL	O
(	O
IQR	O
)	O

6	O
.	O
64	O
(	O
3	O
.	O
75	O
–	O
6	O
.	O
40	O
)	O

5	O
.	O
96	O
(	O
5	O
.	O
27	O
–	O
6	O
.	O
22	O
)	O

0	O
(	O
0	O
–	O
0	O
)	O

0	O
(	O
0	O
–	O
0	O
)	O

<	O
0	O
.	O
001	O

HBV	B-OG
RNA	O
,	O
log10	O
IU	O
/	O
mL	O
(	O
IQR	O
)	O

1	O
.	O
46	O
(	O
0	O
.	O
0	O
–	O
1	O
.	O
87	O
)	O

3	O
.	O
89	O
(	O
3	O
.	O
54	O
–	O
5	O
.	O
27	O
)	O

5	O
.	O
46	O
(	O
4	O
.	O
09	O
–	O
6	O
.	O
07	O
)	O

1	O
.	O
77	O
(	O
1	O
.	O
30	O
–	O
2	O
.	O
42	O
)	O

<	O
0	O
.	O
001	O

PLT	O
10	O
^	O
9	O
/	O
L	O
(	O
range	O
)	O

172	O
(	O
90	O
–	O
377	O
)	O

192	O
(	O
126	O
–	O
286	O
)	O

163	O
(	O
70	O
–	O
261	O
)	O

192	O
.	O
5	O
(	O
62	O
–	O
315	O
)	O

0	O
.	O
188	O

AST	B-GP
,	O
IU	O
/	O
L	O
(	O
range	O
)	O

36	O
(	O
18	O
–	O
120	O
)	O

37	O
(	O
24	O
–	O
75	O
)	O

40	O
.	O
5	O
(	O
25	O
–	O
130	O
)	O

26	O
(	O
12	O
–	O
154	O
)	O

0	O
.	O
004	O

ALT	B-GP
,	O
IU	O
/	O
L	O
(	O
range	O
)	O

41	O
(	O
13	O
–	O
150	O
)	O

36	O
(	O
8	O
–	O
145	O
)	O

39	O
.	O
5	O
(	O
17	O
–	O
98	O
)	O

20	O
.	O
5	O
(	O
7	O
–	O
173	O
)	O

0	O
.	O
009	O

ALP	B-GP
,	O
IU	O
/	O
L	O
(	O
range	O
)	O

74	O
(	O
43	O
–	O
205	O
)	O

76	O
(	O
35	O
–	O
79	O
)	O

86	O
.	O
5	O
(	O
58	O
–	O
173	O
)	O

78	O
(	O
32	O
–	O
149	O
)	O

0	O
.	O
313	O

GGT	B-GP
,	O
IU	O
/	O
L	O
(	O
range	O
)	O

41	O
(	O
16	O
–	O
340	O
)	O

41	O
(	O
14	O
–	O
539	O
)	O

45	O
.	O
5	O
(	O
10	O
–	O
160	O
)	O

29	O
(	O
8	O
–	O
323	O
)	O

0	O
.	O
170	O

TP	O
,	O
g	O
/	O
L	O
(	O
range	O
)	O

76	O
.	O
9	O
(	O
67	O
.	O
3	O
–	O
92	O
.	O
8	O
)	O

74	O
.	O
45	O
(	O
68	O
.	O
2	O
–	O
79	O
.	O
1	O
)	O

73	O
.	O
75	O
(	O
66	O
.	O
2	O
–	O
86	O
.	O
8	O
)	O

75	O
.	O
3	O
(	O
64	O
.	O
6	O
–	O
92	O
.	O
4	O
)	O

0	O
.	O
189	O

ALB	B-GP
,	O
g	O
/	O
L	O
(	O
range	O
)	O

44	O
.	O
3	O
(	O
34	O
.	O
8	O
–	O
55	O
.	O
4	O
)	O

45	O
.	O
85	O
(	O
41	O
.	O
9	O
–	O
49	O
)	O

44	O
.	O
9	O
(	O
33	O
.	O
4	O
–	O
53	O
.	O
3	O
)	O

44	O
.	O
1	O
(	O
33	O
.	O
7	O
–	O
57	O
.	O
2	O
)	O

0	O
.	O
964	O

GLB	B-GP
,	O
g	O
/	O
L	O
(	O
range	O
)	O

32	O
.	O
8	O
(	O
23	O
.	O
6	O
–	O
46	O
.	O
2	O
)	O

28	O
.	O
6	O
(	O
26	O
.	O
3	O
–	O
33	O
)	O

30	O
(	O
22	O
.	O
9	O
–	O
47	O
)	O

30	O
.	O
2	O
(	O
20	O
.	O
6	O
–	O
49	O
.	O
9	O
)	O

0	O
.	O
320	O

TBIL	O
,	O
μmol	O
/	O
L	O
(	O
range	O
)	O

13	O
.	O
9	O
(	O
4	O
.	O
2	O
–	O
36	O
.	O
4	O
)	O

12	O
.	O
9	O
(	O
7	O
.	O
1	O
–	O
38	O
.	O
3	O
)	O

17	O
.	O
2	O
(	O
6	O
–	O
41	O
.	O
4	O
)	O

11	O
.	O
2	O
(	O
5	O
.	O
8	O
–	O
68	O
.	O
5	O
)	O

0	O
.	O
093	O

DBIL	O
,	O
μmol	O
/	O
L	O
(	O
range	O
)	O

4	O
.	O
65	O
(	O
2	O
.	O
1	O
–	O
10	O
.	O
6	O
)	O

3	O
.	O
75	O
(	O
2	O
.	O
6	O
–	O
8	O
.	O
4	O
)	O

4	O
.	O
55	O
(	O
2	O
.	O
2	O
–	O
18	O
.	O
5	O
)	O

3	O
.	O
6	O
(	O
1	O
.	O
9	O
–	O
26	O
.	O
4	O
)	O

0	O
.	O
036	O

IBIL	O
,	O
μmol	O
/	O
L	O
(	O
range	O
)	O

9	O
.	O
5	O
(	O
2	O
.	O
1	O
–	O
26	O
.	O
9	O
)	O

9	O
.	O
15	O
(	O
4	O
.	O
3	O
–	O
29	O
.	O
9	O
)	O

12	O
.	O
9	O
(	O
3	O
.	O
8	O
–	O
32	O
.	O
1	O
)	O

7	O
.	O
8	O
(	O
3	O
.	O
9	O
–	O
42	O
.	O
1	O
)	O

0	O
.	O
489	O

CHE	B-GP
,	O
IU	O
/	O
L	O
(	O
range	O
)	O

7395	O
(	O
1623	O
–	O
12263	O
)	O

7473	O
.	O
5	O
(	O
5169	O
–	O
10112	O
)	O

7190	O
.	O
5	O
(	O
2153	O
–	O
15890	O
)	O

7288	O
.	O
5	O
(	O
1752	O
–	O
13390	O
)	O

0	O
.	O
969	O

BUN	O
,	O
mmol	O
/	O
L	O
(	O
range	O
)	O

5	O
.	O
37	O
(	O
2	O
.	O
7	O
–	O
9	O
.	O
19	O
)	O

4	O
.	O
67	O
(	O
3	O
.	O
28	O
–	O
7	O
.	O
56	O
)	O

4	O
.	O
99	O
(	O
3	O
.	O
48	O
–	O
8	O
.	O
74	O
)	O

5	O
.	O
51	O
(	O
3	O
.	O
77	O
–	O
9	O
.	O
29	O
)	O

0	O
.	O
901	O

Cr	O
,	O
μmol	O
/	O
L	O
(	O
range	O
)	O

64	O
.	O
3	O
(	O
43	O
.	O
8	O
–	O
102	O
.	O
5	O
)	O

67	O
.	O
9	O
(	O
51	O
.	O
1	O
–	O
84	O
)	O

66	O
.	O
7	O
(	O
38	O
.	O
1	O
–	O
120	O
)	O

65	O
.	O
7	O
(	O
43	O
.	O
8	O
–	O
106	O
.	O
4	O
)	O

0	O
.	O
998	O

TG	O
,	O
mmol	O
/	O
L	O
(	O
range	O
)	O

1	O
.	O
2	O
(	O
0	O
.	O
53	O
–	O
12	O
.	O
5	O
)	O

1	O
.	O
24	O
(	O
0	O
.	O
69	O
–	O
2	O
.	O
6	O
)	O

1	O
.	O
25	O
(	O
0	O
.	O
5	O
–	O
4	O
.	O
3	O
)	O

1	O
.	O
29	O
(	O
0	O
.	O
62	O
–	O
7	O
.	O
15	O
)	O

0	O
.	O
783	O

TC	O
,	O
mmol	O
/	O
L	O
(	O
range	O
)	O

4	O
.	O
23	O
(	O
2	O
.	O
9	O
–	O
7	O
.	O
13	O
)	O

4	O
.	O
52	O
(	O
3	O
.	O
61	O
–	O
8	O
.	O
78	O
)	O

4	O
.	O
73	O
(	O
2	O
.	O
82	O
–	O
10	O
.	O
4	O
)	O

4	O
.	O
69	O
(	O
2	O
.	O
8	O
–	O
6	O
.	O
59	O
)	O

0	O
.	O
312	O

GLU	O
,	O
mmol	O
/	O
L	O
(	O
range	O
)	O

4	O
.	O
22	O
(	O
3	O
.	O
01	O
–	O
13	O
.	O
31	O
)	O

4	O
.	O
73	O
(	O
3	O
.	O
32	O
–	O
7	O
.	O
85	O
)	O

3	O
.	O
82	O
(	O
2	O
.	O
69	O
–	O
7	O
.	O
37	O
)	O

3	O
.	O
94	O
(	O
2	O
.	O
81	O
–	O
8	O
.	O
73	O
)	O

0	O
.	O
364	O

APRI	O
level	O
(	O
range	O
)	O

0	O
.	O
23	O
(	O
0	O
.	O
07	O
–	O
1	O
.	O
29	O
)	O

0	O
.	O
25	O
(	O
0	O
.	O
09	O
–	O
0	O
.	O
38	O
)	O

0	O
.	O
27	O
(	O
0	O
.	O
1	O
–	O
1	O
.	O
86	O
)	O

0	O
.	O
13	O
(	O
0	O
.	O
05	O
–	O
2	O
.	O
48	O
)	O

0	O
.	O
014	O

FIB	O
-	O
4	O
level	O
(	O
range	O
)	O

1	O
.	O
98	O
(	O
0	O
.	O
52	O
–	O
8	O
.	O
64	O
)	O

1	O
.	O
63	O
(	O
1	O
.	O
09	O
–	O
3	O
.	O
02	O
)	O

2	O
.	O
1	O
(	O
0	O
.	O
79	O
–	O
12	O
.	O
01	O
)	O

1	O
.	O
42	O
(	O
0	O
.	O
54	O
–	O
11	O
.	O
52	O
)	O

0	O
.	O
166	O

HBsAg	B-GP
level	O
(	O
IQR	O
)	O

7	O
.	O
97	O
(	O
1	O
.	O
12	O
–	O
5122	O
.	O
0	O
)	O

9235	O
.	O
5	O
(	O
6284	O
.	O
25	O
–	O
10455	O
.	O
5	O
)	O

7441	O
.	O
5	O
(	O
6212	O
.	O
0	O
–	O
9163	O
.	O
0	O
)	O

188	O
.	O
6	O
(	O
3	O
.	O
29	O
–	O
6207	O
.	O
5	O
)	O

<	O
0	O
.	O
001	O

HCV	B-OG
core	B-GP
Ag	I-GP
level	O
(	O
fmol	O
/	O
L	O
)	O
(	O
IQR	O
)	O

1726	O
.	O
19	O
(	O
25	O
.	O
8	O
–	O
66116	O
.	O
29	O
)	O

2476	O
.	O
72	O
(	O
609	O
.	O
61	O
–	O
6546	O
.	O
90	O
)	O

2	O
.	O
19	O
(	O
1	O
.	O
75	O
–	O
2	O
.	O
74	O
)	O

2	O
.	O
24	O
(	O
1	O
.	O
82	O
–	O
3	O
.	O
41	O
)	O

<	O
0	O
.	O
001	O

Quantitative	O
variables	O
are	O
displayed	O
as	O
interquartile	O
range	O
(	O
range	O
),	O
and	O
HBsAg	B-GP
,	O
HCV	B-OG
core	B-GP
Ag	I-GP
,	O
HCV	B-OG
-	O
RNA	O
and	O
HBV	B-OG
-	O
DNA	O
which	O
are	O
displayed	O
as	O
interquartile	O
range	O
(	O
IQR	O
),	O
except	O
age	O
and	O
BMI	O
are	O
displayed	O
as	O
interquartile	O
mean	O
±	O
SD	O

BMI	O
,	O
body	O
mass	O
index	O
;	O
ALT	B-GP
,	O
alanine	B-GP
aminotransferase	I-GP
,	O
Normal	O
value	O
:	O
8	O
–	O
50	O
.	O
00	O
U	O
/	O
L	O
;	O
AST	B-GP
,	O
aspartate	B-GP
aminotransferase	I-GP
,	O
Normal	O
value	O
:	O
8	O
–	O
40	O
.	O
00	O
U	O
/	O
L	O
;	O
ALP	B-GP
,	O
alkaline	B-GP
phosphatase	I-GP
,	O
Normal	O
value	O
:	O
15	O
–	O
112	O
.	O
00	O
U	O
/	O
L	O
;	O
GGT	B-GP
,	O
glutamyl	B-GP
transpeptidase	I-GP
,	O
Normal	O
value	O
:	O
5	O
–	O
54	O
.	O
00	O
U	O
/	O
L	O
;	O
TP	O
,	O
total	O
protein	O
,	O
Normal	O
value	O
:	O
60	O
–	O
83	O
.	O
00	O
g	O
/	O
l	O
;	O
ALB	B-GP
,	O
albumin	B-GP
,	O
Normal	O
value	O
:	O
35	O
–	O
55	O
.	O
00	O
g	O
/	O
l	O
;	O
GLB	B-GP
,	O
globulin	B-GP
,	O
Normal	O
value	O
:	O
20	O
–	O
30	O
.	O
00	O
g	O
/	O
L	O
;	O
TBIL	O
,	O
total	O
bilirubin	O
,	O
Normal	O
value	O
:	O
6	O
.	O
8	O
–	O
30	O
.	O
00	O
μmol	O
/	O
L	O
;	O
DBIL	O
,	O
direct	O
bilirubin	O
,	O
Normal	O
value	O
:	O
0	O
–	O
8	O
.	O
60	O
μmol	O
/	O
L	O
;	O
IBIL	O
,	O
indirect	O
bilirubin	O
,	O
Normal	O
value	O
:	O
5	O
.	O
1	O
–	O
21	O
.	O
40	O
umol	O
/	O
L	O
;	O
CHE	B-GP
,	O
cholinesterase	B-GP
,	O
Normal	O
value	O
:	O
4300	O
–	O
12000	O
.	O
00	O
U	O
/	O
L	O
;	O
BUN	O
,	O
blood	O
urea	O
nitrogen	O
,	O
Normal	O
value	O
:	O
3	O
.	O
2	O
–	O
7	O
.	O
00	O
mmol	O
/	O
L	O
;	O
Cr	O
,	O
creatinine	O
,	O
Normal	O
value	O
:	O
44	O
–	O
115	O
.	O
00	O
μmol	O
/	O
L	O
;	O
TG	O
,	O
triglycerides	O
,	O
Normal	O
value	O
:	O
0	O
.	O
28	O
–	O
1	O
.	O
80	O
mmol	O
/	O
L	O
;	O
TC	O
,	O
total	O
cholesterol	O
,	O
Normal	O
value	O
:	O
2	O
.	O
6	O
–	O
6	O
.	O
00	O
mmol	O
/	O
L	O
;	O
GLU	O
,	O
glucose	O
,	O
Normal	O
value	O
:	O
3	O
.	O
9	O
–	O
6	O
.	O
10	O
mmol	O
/	O
L	O
;	O
PLT	O
,	O
platelet	O
,	O
Normal	O
value	O
:	O
100	O
–	O
300	O
.	O
00	O
10	O
^	O
9	O
/	O
L	O
;	O
APRI	O
,	O
aspartate	B-GP
aminotransferase	I-GP
to	O
platelet	O
ratio	O
index	O
;	O
FIB	O
-	O
4	O
,	O
fibrosis	O
index	O
based	O
on	O
the	O
four	O
factors	O
score	O

Because	O
HBsAg	B-GP
did	O
not	O
correlate	O
with	O
HBV	B-OG
DNA	O
and	O
HCV	B-OG
RNA	O
in	O
the	O
overall	O
cohort	O
,	O
we	O
analyzed	O
patterns	O
of	O
HBV	B-OG
and	O
HCV	B-OG
dominance	O
in	O
co	O
-	O
infected	O
patients	O
.	O

Twenty	O
patients	O
(	O
18	O
.	O
69	O
%)	O
showed	O
HBV	B-OG
dominance	O
(	O
Group	O
c	O
)	O
(	O
HBV	B-OG
DNA	O
>	O
2000	O
IU	O
/	O
mL	O
and	O
HCV	B-OG
RNA	O
<	O
15	O
IU	O
/	O
mL	O
).	O

The	O
majority	O
of	O
HBV	B-OG
-	O
HCV	B-OG
co	O
-	O
infected	O
patients	O
(	O
n	O
=	O
39	O
,	O
36	O
.	O
45	O
%)	O
were	O
HCV	B-OG
dominant	O
(	O
Group	O
a	O
)	O
(	O
HBV	B-OG
DNA	O
<	O
2000	O
IU	O
/	O
mL	O
and	O
HCV	B-OG
RNA	O
>	O
15	O
IU	O
/	O
mL	O
).	O

In	O
8	O
(	O
7	O
.	O
48	O
%)	O
patients	O
significant	O
replication	O
of	O
both	O
viruses	B-OG
was	O
detected	O
(	O
Group	O
b	O
);	O
whereas	O
in	O
40	O
(	O
37	O
.	O
38	O
%)	O
patients	O
,	O
neither	O
of	O
the	O
viruses	B-OG
were	O
significantly	O
replicating	O
(	O
Group	O
d	O
)	O
(	O
Table	O
5	O
).	O

The	O
baseline	O
characteristics	O
of	O
the	O
four	O
groups	O
of	O
patients	O
did	O
not	O
significantly	O
differ	O
.	O

Interestingly	O
,	O
HBsAg	B-GP
levels	O
were	O
significantly	O
different	O
between	O
the	O
groups	O
(	O
analysis	O
of	O
variance	O
,	O
p	O
<	O
0	O
.	O
001	O
).	O

As	O
expected	O
,	O
HBsAg	B-GP
levels	O
were	O
highest	O
in	O
patients	O
with	O
HBV	B-OG
DNA	O
(>	O
2000	O
IU	O
/	O
mL	O
)	O
(	O
Group	O
b	O
:	O
9235	O
.	O
5	O
[	O
IQR	O
,	O
6284	O
.	O
25	O
–	O
10455	O
.	O
5	O
],	O
Group	O
c	O
:	O
7441	O
.	O
5	O
[	O
IQR	O
,	O
6212	O
.	O
0	O
–	O
9163	O
.	O
0	O
]),	O
lower	O
in	O
patients	O
without	O
HBV	B-OG
dominance	O
(	O
Group	O
a	O
:	O
7	O
.	O
97	O
[	O
IQR	O
,	O
1	O
.	O
12	O
–	O
5122	O
.	O
0	O
],	O
Group	O
d	O
:	O
188	O
.	O
6	O
[	O
IQR	O
,	O
3	O
.	O
29	O
–	O
6207	O
.	O
5	O
]),	O
and	O
lowest	O
in	O
patients	O
with	O
HCV	B-OG
dominance	O
(	O
Table	O
5	O
).	O

Correlation	O
between	O
HCV	B-OG
and	O
HBV	B-OG
Serum	O
Markers	O

We	O
found	O
a	O
significant	O
negative	O
correlation	O
between	O
HCV	B-OG
RNA	O
load	O
or	O
HCV	B-OG
core	B-GP
Ag	I-GP
level	O
with	O
HBV	B-OG
DNA	O
load	O
(	O
r	O
=	O
-	O
0	O
.	O
276	O
and	O
r	O
=	O
-	O
0	O
.	O
242	O
)	O
(	O
Table	O
6	O
).	O

There	O
was	O
a	O
negative	O
correlation	O
between	O
HBsAg	B-GP
levels	O
and	O
HCV	B-OG
RNA	O
(	O
r	O
=	O
-	O
0	O
.	O
200	O
,	O
p	O
=	O
0	O
.	O
039	O
).	O

As	O
expected	O
,	O
high	O
correlations	O
were	O
found	O
between	O
the	O
HCV	B-OG
RNA	O
load	O
and	O
HCV	B-OG
core	B-GP
Ag	I-GP
level	O
(	O
r	O
=	O
0	O
.	O
781	O
)	O
as	O
well	O
as	O
between	O
the	O
HBV	B-OG
DNA	O
load	O
and	O
HBsAg	B-GP
level	O
(	O
r	O
=	O
0	O
.	O
558	O
)	O
in	O
patients	O
with	O
HBV	B-DS
-	I-DS
HCV	I-DS
co	I-DS
-	I-DS
infecton	I-DS
(	O
Table	O
6	O
).	O

Correlation	O
of	O
serum	O
markers	O
in	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
patients	O
(	O
n	O
=	O
107	O
).	O


HCV	B-OG
RNA	O
log10	O
IU	O
/	O
mL	O

HCV	B-OG
core	B-GP
Ag	I-GP
level	O
(	O
fmol	O
/	O
L	O
)	O

HBV	B-OG
DNA	O
log10	O
IU	O
/	O
mL	O

HBsAg	B-GP
level	O
(	O
fmol	O
/	O
L	O
)	O

HCV	B-OG
RNA	O
log10	O
IU	O
/	O
mL	O

1	O
.	O
000	O

0	O
.	O
781	O
**	O

-	O
0	O
.	O
276	O
**	O

-	O
0	O
.	O
200	O
*	O

HCV	B-OG
core	B-GP
Ag	I-GP
level	O
(	O
fmol	O
/	O
L	O
)	O


1	O
.	O
000	O

-	O
0	O
.	O
242	O
*	O

-	O
0	O
.	O
161	O

HBV	B-OG
DNA	O
log10	O
IU	O
/	O
mL	O



1	O
.	O
000	O

0	O
.	O
558	O
**	O

HBsAg	B-GP
level	O




1	O
.	O
000	O

**	O
P	O
<	O
0	O
.	O
01	O
,	O
Pair	O
-	O
wise	O
Spearman	O
correlation	O
analysis	O

*	O
P	O
<	O
0	O
.	O
05	O
,	O
Pair	O
-	O
wise	O
Spearman	O
correlation	O
analysis	O

Discussion	O

Among	O
the	O
patients	O
included	O
in	O
this	O
study	O
,	O
we	O
found	O
that	O
8	O
.	O
4	O
%	O
of	O
those	O
with	O
chronic	O
HCV	B-OG
infection	B-DS
were	O
co	O
-	O
infected	O
with	O
HBV	B-OG
.	O

In	O
China	O
,	O
the	O
prevalence	O
of	O
HCV	B-OG
is	O
approximately	O
0	O
.	O
43	O
%	O
in	O
the	O
population	O
between	O
the	O
ages	O
of	O
1	O
and	O
59	O
[	O
25	O
].	O

Therefore	O
,	O
there	O
may	O
be	O
a	O
large	O
number	O
of	O
patients	O
in	O
China	O
who	O
are	O
co	O
-	O
infected	O
with	O
HCV	B-OG
and	O
HBV	B-OG
.	O

Our	O
study	O
evaluated	O
the	O
proportion	O
of	O
HCV	B-OG
-	O
infected	O
patients	O
from	O
an	O
HCV	B-OG
-	O
endemic	O
region	O
in	O
northeast	O
China	O
who	O
were	O
exposed	O
to	O
HBV	B-OG
,	O
as	O
well	O
as	O
the	O
proportion	O
of	O
subjects	O
who	O
were	O
co	O
-	O
infected	O
with	O
HBV	B-OG
.	O

We	O
obtained	O
data	O
from	O
a	O
substantial	O
number	O
of	O
patients	O
,	O
which	O
suggests	O
that	O
HCV	B-OG
and	O
HBV	B-OG
mutually	O
inhibit	O
the	O
other	O
virus	B-OG
’	O
s	O
replication	O
in	O
co	O
-	O
infected	O
patients	O
.	O

Our	O
virological	O
data	O
suggest	O
that	O
the	O
interaction	O
between	O
the	O
viruses	B-OG
,	O
which	O
ultimately	O
determines	O
the	O
progression	O
of	O
chronic	B-DS
hepatitis	I-DS
,	O
might	O
be	O
characterized	O
by	O
reciprocal	O
replication	O
inhibition	O
of	O
the	O
respective	O
viruses	B-OG
.	O

However	O
,	O
whether	O
the	O
order	O
of	O
acquisition	O
of	O
virus	B-DS
infection	I-DS
plays	O
a	O
role	O
in	O
determining	O
the	O
degree	O
of	O
suppression	O
remains	O
to	O
be	O
established	O
.	O

The	O
virological	O
patterns	O
of	O
HBV	B-OG
and	O
HCV	B-DS
infections	I-DS
have	O
been	O
investigated	O
in	O
a	O
large	O
number	O
of	O
clinical	O
studies	O
[	O
3	O
,	O
26	O
]	O
Most	O
of	O
these	O
studies	O
were	O
cross	O
-	O
sectional	O
evaluations	O
of	O
HBV	B-OG
and	O
HCV	B-OG
viral	O
loads	O
observed	O
at	O
a	O
single	O
time	O
point	O
,	O
showing	O
an	O
apparent	O
dominant	O
role	O
of	O
HCV	B-OG
(	O
i	O
.	O
e	O
.,	O
high	O
HCV	B-OG
RNA	O
and	O
low	O
HBV	B-OG
DNA	O
levels	O
)	O
in	O
the	O
majority	O
of	O
the	O
cases	O
.	O

However	O
,	O
other	O
reports	O
suggest	O
reciprocal	O
interference	O
or	O
a	O
dominant	O
effect	O
of	O
HBV	B-OG
[	O
5	O
,	O
27	O
–	O
29	O
].	O

Furthermore	O
,	O
ethnic	O
factors	O
that	O
may	O
influence	O
the	O
dominant	O
role	O
of	O
one	O
virus	B-OG
over	O
the	O
other	O
have	O
been	O
proposed	O
[	O
30	O
];	O
however	O
,	O
this	O
phenomenon	O
is	O
not	O
well	O
understood	O
,	O
and	O
the	O
mechanisms	O
by	O
which	O
this	O
occurs	O
have	O
yet	O
to	O
be	O
established	O
[	O
31	O
,	O
32	O
].	O

We	O
found	O
a	O
marked	O
difference	O
in	O
the	O
severity	O
of	O
liver	B-DS
disease	I-DS
among	O
the	O
HCV	B-OG
mono	O
-	O
infected	O
,	O
HBV	B-OG
mono	O
-	O
infected	O
,	O
and	O
HBV	B-OG
-	O
HCV	B-OG
co	O
-	O
infected	O
groups	O
(	O
Table	O
1	O
).	O

Indeed	O
,	O
similar	O
differences	O
in	O
the	O
clinical	O
presentation	O
of	O
liver	B-DS
disease	I-DS
were	O
reported	O
in	O
a	O
recent	O
study	O
of	O
1257	O
patients	O
from	O
New	O
York	O
City	O
with	O
chronic	O
HCV	B-OG
infection	B-DS
,	O
including	O
26	O
patients	O
with	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
[	O
1	O
].	O

Other	O
studies	O
have	O
also	O
confirmed	O
that	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
is	O
associated	O
with	O
more	O
advanced	O
liver	B-DS
disease	I-DS
compared	O
to	O
HBV	B-OG
or	O
HCV	B-OG
mono	O
-	O
infection	B-DS
[	O
5	O
,	O
8	O
,	O
28	O
,	O
33	O
–	O
36	O
].	O

The	O
frequency	O
of	O
HBeAg	B-GP
negativity	O
is	O
significantly	O
higher	O
in	O
patients	O
with	O
HBV	B-OG
-	O
HCV	B-OG
co	O
-	O
infected	O
patients	O
compared	O
to	O
those	O
with	O
HBV	B-OG
mono	O
-	O
infection	B-DS
.	O

It	O
is	O
possible	O
that	O
HBeAg	B-GP
-	O
negative	O
patients	O
had	O
seroconversion	O
to	O
anti	O
-	O
Hbe	O
before	O
becoming	O
inactive	O
carriers	O
.	O

Similarly	O
,	O
in	O
a	O
6	O
-	O
year	O
follow	O
-	O
up	O
study	O
,	O
Sheen	O
et	O
al	O
.	O
found	O
a	O
rate	O
of	O
HBsAg	B-GP
clearance	O
2	O
.	O
5	O
times	O
faster	O
in	O
HBsAg	B-GP
/	O
anti	O
-	O
HCV	B-OG
-	O
positive	O
patients	O
than	O
in	O
those	O
with	O
HBV	B-DS
infection	I-DS
alone	O
[	O
37	O
].	O

Ohkawa	O
et	O
al	O
.	O
[	O
30	O
]	O
and	O
Pontisso	O
et	O
al	O
.	O
[	O
29	O
]	O
observed	O
a	O
reciprocal	O
inhibitory	O
effect	O
between	O
HBV	B-OG
and	O
HCV	B-OG
in	O
small	O
groups	O
of	O
patients	O
.	O

In	O
addition	O
,	O
Shih	O
et	O
al	O
.	O
observed	O
suppression	O
of	O
HBV	B-OG
expression	O
and	O
replication	O
by	O
the	O
core	B-GP
protein	I-GP
of	O
HCV	B-OG
in	O
cell	O
culture	O
[	O
38	O
].	O

If	O
HBV	B-OG
and	O
HCV	B-OG
infect	O
the	O
same	O
hepatocyte	O
,	O
HCV	B-OG
structural	O
or	O
functional	O
proteins	O
may	O
directly	O
influence	O
HBV	B-OG
replication	O
and	O
HBsAg	B-GP
expression	O
,	O
or	O
vice	O
versa	O
[	O
39	O
].	O

For	O
example	O
,	O
HBsAg	B-GP
antigen	O
expression	O
and	O
viremia	B-DS
are	O
lower	O
in	O
the	O
livers	O
of	O
HBV	B-OG
-	O
HCV	B-OG
co	O
-	O
infected	O
patients	O
[	O
16	O
].	O

These	O
findings	O
and	O
results	O
from	O
the	O
multivariate	O
analysis	O
of	O
our	O
follow	O
-	O
up	O
study	O
suggest	O
HCV	B-OG
is	O
accountable	O
for	O
enhanced	O
HBsAg	B-GP
seroclearance	O
in	O
chronic	O
HBV	B-DS
infection	I-DS
[	O
37	O
].	O

A	O
recent	O
case	O
-	O
control	O
study	O
found	O
that	O
patients	O
with	O
chronic	O
HBV	B-DS
infection	I-DS
who	O
had	O
serum	O
HBsAg	B-GP
clearance	O
had	O
a	O
significantly	O
higher	O
prevalence	O
of	O
anti	O
-	O
HCV	B-OG
antibodies	B-GP
than	O
age	O
-	O
and	O
sex	O
-	O
matched	O
controls	O
patients	O
(	O
31	O
.	O
4	O
%	O
versus	O
5	O
.	O
9	O
%;	O
P	O
<	O
0	O
.	O
001	O
)	O
[	O
40	O
].	O

This	O
observation	O
provides	O
indirect	O
evidence	O
to	O
support	O
the	O
concept	O
that	O
HCV	B-DS
superinfection	I-DS
exerts	O
viral	O
interference	O
that	O
can	O
suppress	O
or	O
terminate	O
a	O
chronic	O
HBsAg	B-GP
carrier	O
state	O
.	O

Other	O
recent	O
studies	O
have	O
discussed	O
indirect	O
mechanisms	O
that	O
may	O
be	O
involved	O
.	O

Bellecave	O
et	O
al	O
.	O
showed	O
in	O
vitro	O
that	O
HBV	B-OG
and	O
HCV	B-OG
can	O
replicate	O
in	O
the	O
same	O
cell	O
without	O
direct	O
viral	O
interference	O
[	O
31	O
].	O

Wiegand	O
et	O
al	O
.	O
found	O
higher	O
interferon	B-GP
-	I-GP
gamma	I-GP
-	I-GP
inducible	I-GP
protein	I-GP
-	I-GP
10	I-GP
(	O
IP	B-GP
-	I-GP
10	I-GP
)	O
levels	O
in	O
HCV	B-OG
-	O
dominant	O
HBV	B-OG
-	O
HCV	B-OG
co	O
-	O
infected	O
patients	O
,	O
which	O
suggests	O
that	O
immune	O
mechanisms	O
may	O
be	O
responsible	O
for	O
HCV	B-OG
suppressing	O
HBV	B-OG
DNA	O
replication	O
and	O
HBsAg	B-GP
production	O
[	O
41	O
].	O

As	O
we	O
anticipated	O
,	O
there	O
was	O
a	O
significant	O
negative	O
correlation	O
between	O
HCV	B-OG
RNA	O
load	O
or	O
HCV	B-OG
core	B-GP
Ag	I-GP
level	O
and	O
HBV	B-OG
DNA	O
load	O
as	O
well	O
as	O
between	O
HBsAg	B-GP
levels	O
and	O
HCV	B-OG
RNA	O
levels	O
(	O
Table	O
6	O
).	O

The	O
values	O
were	O
similar	O
to	O
those	O
reported	O
by	O
Wiegand	O
et	O
al	O
.[	O
41	O
],	O
which	O
showed	O
that	O
,	O
overall	O
,	O
HBsAg	B-GP
levels	O
had	O
a	O
positive	O
correlation	O
with	O
HBV	B-OG
DNA	O
(	O
r	O
=	O
0	O
.	O
52	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
a	O
negative	O
correlation	O
with	O
HCV	B-OG
RNA	O
levels	O
(	O
r	O
=	O
-	O
0	O
.	O
20	O
,	O
p	O
=	O
0	O
.	O
06	O
).	O

Therefore	O
,	O
although	O
a	O
significantly	O
higher	O
percentage	O
of	O
patients	O
had	O
a	O
lower	O
HBsAg	B-GP
level	O
(<	O
1000	O
IU	O
/	O
mL	O
)	O
in	O
the	O
co	B-DS
-	I-DS
infection	I-DS
group	O
compared	O
to	O
the	O
HBV	B-OG
mono	O
-	O
infection	B-DS
group	O
,	O
the	O
negative	O
correlation	O
between	O
HBsAg	B-GP
levels	O
and	O
HCV	B-OG
RNA	O
levels	O
implies	O
that	O
the	O
interplay	O
between	O
HBV	B-OG
and	O
HCV	B-OG
may	O
be	O
not	O
the	O
result	O
of	O
HBsAg	B-GP
.	O

It	O
is	O
therefore	O
important	O
to	O
look	O
for	O
host	O
factors	O
that	O
may	O
influence	O
the	O
difference	O
in	O
viral	O
load	O
and	O
serum	O
markers	O
observed	O
in	O
patients	O
with	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
.	O

Clearly	O
,	O
further	O
research	O
in	O
this	O
important	O
area	O
is	O
warranted	O
.	O

Our	O
study	O
was	O
a	O
cross	O
-	O
sectional	O
study	O
based	O
on	O
demographic	O
and	O
clinical	O
data	O
collected	O
from	O
a	O
large	O
number	O
of	O
samples	O
.	O

We	O
did	O
not	O
evaluate	O
the	O
long	O
-	O
term	O
outcomes	O
of	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
.	O

Because	O
HBV	B-OG
-	O
HCV	B-OG
viremia	B-DS
is	O
a	O
dynamic	O
process	O
[	O
7	O
],	O
long	O
-	O
term	O
follow	O
-	O
up	O
will	O
be	O
critical	O
to	O
understanding	O
the	O
complex	O
interactions	O
between	O
HBV	B-OG
and	O
HCV	B-OG
in	O
co	O
-	O
infected	O
patients	O
.	O

We	O
don	O
'	O
t	O
have	O
to	O
HCV	B-OG
mono	O
-	O
infection	B-DS
group	O
(	O
HBsAg	B-GP
-	O
negative	O
patients	O
)	O
with	O
HBV	B-OG
DNA	O
testing	O
;	O
therefore	O
,	O
we	O
may	O
missed	O
the	O
occult	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
with	O
HBV	B-OG
(	O
HBsAg	B-GP
-	O
negative	O
with	O
detectable	O
HBV	B-OG
DNA	O
),	O
and	O
we	O
may	O
have	O
underestimated	O
the	O
actual	O
prevalence	O
of	O
HBV	B-OG
-	O
HCV	B-OG
co	B-DS
-	I-DS
infection	I-DS
.	O

HBV	B-OG
-	O
HCV	B-OG
co	O
-	O
infected	O
patients	O
exhibited	O
severe	O
liver	O
injury	O
,	O
which	O
is	O
consistent	O
with	O
a	O
very	O
high	O
risk	O
of	O
liver	B-DS
cancer	I-DS
among	O
these	O
individuals	O
[	O
42	O
,	O
43	O
].	O

Therefore	O
,	O
tests	O
should	O
to	O
be	O
performed	O
to	O
detect	O
for	O
co	O
-	O
infected	O
patients	O
to	O
proactively	O
screen	O
for	O
liver	B-DS
cancer	I-DS
,	O
and	O
aggressive	O
treatment	O
may	O
be	O
required	O
for	O
these	O
patients	O
.	O

Supporting	O
Information	O

Original	O
data	O
used	O
in	O
this	O
study	O
.	O

(	O
XLS	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

